BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

InFocus : Cambrian Bioworks Enhances Global Healthcare with Automated Molecular Diagnostics

NextEdge Admin

03 Sep 2024

2 min 59 sec

Molecular Diagnostics,personalized medicine

Founded in 2020 by Hegde, Rohit Asil, and Raghav Sridhar, Cambrian Bioworks, a Bengaluru-based biotechnology startup, specializes in the development of automated molecular diagnostics platforms. These platforms are designed to revolutionize the detection and analysis of various diseases, with applications in oncology, genomics, rare disease testing, and antimicrobial resistance (AMR) detection.

Cambrian Bioworks, has recently successfully raised $1.45 million (INR 12 Cr) in a seed funding round led by the Irani family office, with additional participation from the company’s cofounder and CEO, Vaibhav Hegde.

The newly secured funding will be instrumental in scaling up Cambrian Bioworks' operations, particularly in the areas of research and development, team expansion, and international market penetration. The company aims to enhance its automated platforms, ensuring they are not only cutting-edge but also accessible to a broader range of healthcare providers globally. A significant focus will be on improving the efficiency and accuracy of diagnostic tools, which are critical in fields like liquid biopsy testing, where precision is paramount.

One of the company's flagship products is Manta, a nucleic acid extraction device that streamlines the process of preparing samples for molecular diagnostics. Manta is a key component in Cambrian Bioworks' strategy to expand its reach in the liquid biopsy market, enabling quicker, more accurate detection of cancer and other diseases through non-invasive methods. The device is designed to integrate seamlessly with the company's broader suite of diagnostic tools, facilitating a more comprehensive and automated approach to disease testing.

Cambrian Bioworks is also dedicated to advancing DNA sequencing and molecular rewrite technologies, which are vital for the next generation of personalized medicine. By focusing on automation and precision, the company is poised to play a significant role in the global healthcare landscape, driving innovation in diagnostics and contributing to more effective, targeted treatments for patients worldwide.